Page 36 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 36

                                Chapter 2
assuming a residence time of 113 h for the entire patient. This simplified procedure showed only a minor decrease of the estimated effective dose: 0.44 ±0.002 mSv/ MBq in males and 0.54 ± 0.002 mSv/MBq in females. Difference in estimated effective dose between males and females, with versus without ignoring the biodistribution, suggests that this difference might be explained by use of different models (male versus female) within OLINDA/EXM 1.0.
The normal organs with the highest absorbed dose were the liver (mean dose in males 1.25 ± 0.27 mSv/MBq; in females 1.35 ± 0.21 mSv/MBq) and kidneys (mean dose in males 0.82 ± 0.15 mSv/MBq; in females 1.18 ± 0.26 mSv/MBq).
Table 4. Absorbed organ doses
 Patient no.
Kidneys
Liver
1.60
1.47
1.20
1.17
1.48
1.55
1.01
1.23
0.69
1.14
1.23
1.25 ± 0.27
1.31
1.19
1.15
1.56
1.65
1.09
1.52
1.33
1.35 ± 0.21
Lungs
0.93
0.83
0.68
1.01
0.54
0.53
0.44
0.50
0.42
0.54
0.49
0.63 ± 0.20
0.63
0.84
0.96
1.01
1.11
1.05
1.12
0.83
0.94 ± 0.17
Spleen
0.74
0.66
0.74
0.71
0.81
0.82
0.58
0.57
0.47
0.59
0.70
0.67 ± 0.11
0.89
0.86
0.62
0.87
0.86
0.84
0.64
0.55
0.77 ± 0.14
Thyroid
1.28
NV
0.70
NV
1.40
NV
0.86
0.70
0.72
0.85
0.81
0.91 ± 0.27
1.12
NV
NV
0.93
NV
1.44
1.11
0.98
1.12 ± 0.20
Males
2 1.01 5 0.85 7 0.86 8 0.84 11 0.96 12 1.01 14 0.73 15 0.69 17 0.58 19 0.80 20 0.64 Mean ± SD 0.82 Females
1 1.26 3 1.12 4 0.87 6 1.32 9 0.99 10 1.04 13 1.71 16 1.15 Mean ± SD 1.18
Abbreviations: NV,
± 0.15
0.44 ± 0.0022
0.53 ± 0.03
Organ dose (mSv/MBq)
Effective dose (mSv/MBq)
Total body Organ dosimetry
0.45 0.60 0.45 0.54 0.44 0.53 0.44 0.55 0.45 0.56 0.45 0.52 0.44 0.52 0.44 0.52 0.44 0.49 0.44 0.52 0.44 0.52
    0.54 0.64 0.54 0.65 0.54 0.63 0.55 0.67 0.55 0.66 0.54 0.69 0.55 0.71 0.54 0.65
 ± 0.26 not visible
0.54 ± 0.0024
0.66 ± 0.03
 34
   34   35   36   37   38